Evidence map›Paper›PMID 33614448›Full record

ArticleInternational journal of ophthalmology2021

Retrobulbar administration of purified anti-nerve growth factor in developing rats induces structural and biochemical changes in the retina and cornea.

Luigi Aloe, Maria Luisa Rocco, Bijorn Omar Balzamino, Graziana Esposito, Alessandra Micera

Open access · goldAbstract read
In one paragraph

Article in International journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Luigi AloeInstitute of Cell Biology and Neurobiology, CNR, Lazio 00143, Rome, Italy.
Maria Luisa RoccoFondazione IRET, Ozzano Emilia, Bologna 40064, Italy.
Bijorn Omar BalzaminoResearch and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Science, IRCCS, Fondazione Bietti, Rome 00182, Italy.
Graziana EspositoResearch and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Science, IRCCS, Fondazione Bietti, Rome 00182, Italy.
Alessandra MiceraResearch and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Science, IRCCS, Fondazione Bietti, Rome 00182, Italy.
Fondazione G.B. Bietti · ITFondazione IRET ONLUS · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo develop an experimental model of endogenous nerve growth factor (NGF) deprivation by retrobulbar administration of purified neutralizing anti-NGF antibodies in young Sprague-Dawley rats and provide further information on NGF expression in the retina and cornea.

methodsSixty old pathogen-free Sprague Dawley rats (p14, post-natal days) were treated with repeated retrobulbar injections of neutralizing anti-NGF (2 µL, 100 µg/mL, every 3d). After 2wk (p28), retinal and corneal tissues were investigated for morphological, biochemical, and molecular expression of trkA

resultsChronic retrobulbar neutralizing anti-NGF antibodies changed the distribution of trkA

conclusionThe reduced availability of endogenous NGF, as produced by chronic retrobulbar anti-NGF administration, produce a quick response from retinal tissues, with respect to corneal ones, suggesting the presence of early compensatory mechanisms to protect retinal networking.

Indexed as

anti-nerve growth factorcorneaphotoreceptorsretinatissue responsetrkANGFR

Identifiers

PMID33614448
PMCPMC7840360
OpenAlexW3124663679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.